ClinicalTrials.gov term: Lymphoma, Large B-Cell, Diffuse
50 trials changed in the last 30 days: 0 stopped, 20 with notable changes, 30 with minor changes only.
Primary completion pushed from Dec 31, 2026 to Jul 31, 2027
Also in this update: Primary endpoint(s) modified; Enrollment increased: 21 → 27 participants
Estrella Immunopharma, Inc.Phase 1/2 NCT06343311 Registry history of NCT06343311 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 2027 to Sep 2028
Eli Lilly and CompanyPhase 1 NCT07226843 Registry history of NCT07226843 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 31, 2026 to Mar 31, 2027
Also in this update: Recruitment opened; Study completion pushed from Jul 31, 2026 to Jul 31, 2027
Shanghai Zhongshan HospitalPhase 2 NCT07012980 Registry history of NCT07012980 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 1, 2026 to Dec 1, 2026
University of RochesterPhase 2 NCT03758989 Registry history of NCT03758989 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 1, 2026 to Aug 1, 2027
Also in this update: Study completion pushed from Aug 1, 2027 to Aug 1, 2028
British Columbia Cancer AgencyPhase 1 NCT06208735 Registry history of NCT06208735 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Mar 23, 2027 to Aug 24, 2029
City of Hope Medical CenterPhase 2 NCT05672251 Registry history of NCT05672251 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 1, 2027 to Aug 1, 2027
Also in this update: Study completion pushed from Jan 1, 2028 to Aug 1, 2028
Marcela V. Maus, M.D.,Ph.D.Phase 1 NCT06026319 Registry history of NCT06026319 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 1, 2026 to Aug 1, 2027
Also in this update: Interventions modified; Study completion pushed from Aug 1, 2027 to Aug 1, 2028
Marcela V. Maus, M.D.,Ph.D.Phase 2 NCT06550141 Registry history of NCT06550141 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 2025 to Jun 2027
Also in this update: Enrollment closed, study ongoing; Study completion pushed from Dec 2027 to Sep 2028
University Medical Center GroningenPhase 2 NCT05641428 Registry history of NCT05641428 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 2, 2026 to Aug 11, 2027
City of Hope Medical CenterPhase 1 NCT02153580 Registry history of NCT02153580 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 8, 2026 to Aug 9, 2027
City of Hope Medical CenterPhase 1 NCT02337985 Registry history of NCT02337985 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Recruitment opened; Primary completion moved earlier from Oct 1, 2029 to Mar 1, 2028
Vanderbilt-Ingram Cancer CenterPhase 2 NCT07763210 Registry history of NCT07763210 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 2/3 → Phase 1
University of Illinois at ChicagoPhase 1 NCT07647432 Registry history of NCT07647432 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 1 → Phase 1/2
University of WashingtonPhase 1/2 NCT04231877 Registry history of NCT04231877 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 62 locations
SWOG Cancer Research NetworkPhase 3 NCT07220187 Registry history of NCT07220187 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Umoja BiopharmaPhase 1/2 NCT07735533 Registry history of NCT07735533 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 24, 2026 to Oct 8, 2026
Shanghai Junshi Bioscience Co., Ltd.Phase 3 NCT07808827 Registry history of NCT07808827 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Nathan DenlingerPhase 1 NCT07676877 Registry history of NCT07676877 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Oct 15, 2026 to Sep 13, 2026
UCARsgen Biotech LimitedPhase 1/2 NCT07823829 Registry history of NCT07823829 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 7, 2026
H. Lee Moffitt Cancer Center and Research InstitutePhase 2 NCT04745559 Registry history of NCT04745559 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Pell Bio-Med Technology Co., Ltd.Phase 1/2 NCT05326243 Registry history of NCT05326243 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 539 participants (planned 700)
Janssen Research & Development, LLCPhase 3 NCT01804686 Registry history of NCT01804686 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3 NCT06929624 Registry history of NCT06929624 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Nov 12, 2026 to May 23, 2026
HutchmedPhase 2 NCT06601504 Registry history of NCT06601504 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Apr 1, 2028 to Aug 13, 2028
National Cancer Institute (NCI)Phase 2/3 NCT03984448 Registry history of NCT03984448 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Hoffmann-La RocheNot specified NCT05954910 Registry history of NCT05954910 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Apr 1, 2027 to Aug 1, 2027
National Cancer Institute (NCI)Phase 1 NCT04609046 Registry history of NCT04609046 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Nov 2026 to Mar 2027
Also in this update: Study completion pushed from Nov 2029 to Mar 2030
BeOne MedicinesPhase 1/2 NCT05006716 Registry history of NCT05006716 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 31, 2027 to Sep 29, 2026; Final enrollment: 74 participants (planned 100)
Beijing Tongren HospitalPhase 2 NCT07461831 Registry history of NCT07461831 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion pushed from Dec 10, 2020 to Jan 14, 2021; Study completion date changed from estimate of May 2, 2027 to Feb 24, 2022
Alliance for Clinical Trials in OncologyPhase 2 NCT01511562 Registry history of NCT01511562 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 31, 2026 to Aug 28, 2026
David Bond, MDPhase 1/2 NCT03015896 Registry history of NCT03015896 on ClinicalTrials.gov (opens the registry)
Trial completed
Fred Hutchinson Cancer CenterPhase 1 NCT05359211 Registry history of NCT05359211 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 40 participants (planned 50)
Gustave Roussy, Cancer Campus, Grand ParisNot applicable NCT06813573 Registry history of NCT06813573 on ClinicalTrials.gov (opens the registry)
Sponsor refiled this as recruiting (was completed)
British Columbia Cancer AgencyNot specified NCT06224309 Registry history of NCT06224309 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
OWKINNot specified NCT06625203 Registry history of NCT06625203 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 278 → 283 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT06717347 Registry history of NCT06717347 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 3, 2027 to Jun 10, 2027
Also in this update: Study completion pushed from Mar 3, 2027 to Sep 9, 2028
Mayo ClinicPhase 2 NCT06834373 Registry history of NCT06834373 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 14 → 20 locations
And 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 1 NCT07332507 Registry history of NCT07332507 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 68 → 82 locations
AstraZenecaPhase 3 NCT07215585 Registry history of NCT07215585 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 42 locations
Kite, A Gilead CompanyPhase 3 NCT07479797 Registry history of NCT07479797 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 87 → 95 locations
SWOG Cancer Research NetworkPhase 2 NCT05633615 Registry history of NCT05633615 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 190 → 194 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT06091865 Registry history of NCT06091865 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 41 → 46 locations
Merck Sharp & Dohme LLCPhase 1/2 NCT07519772 Registry history of NCT07519772 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 104 → 113 locations
And 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT06649812 Registry history of NCT06649812 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 19 locations
Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaPhase 2 NCT07126236 Registry history of NCT07126236 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Apr 2027 to Nov 2031
Also in this update: Primary completion moved earlier from Apr 2027 to Jan 2027
AbbViePhase 1 NCT06667687 Registry history of NCT06667687 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Aug 31, 2028 to Apr 3, 2028
Also in this update: Primary completion date changed from estimate of Jan 31, 2027 to Sep 26, 2026
Washington University School of MedicinePhase 1 NCT05412290 Registry history of NCT05412290 on ClinicalTrials.gov (opens the registry)
Interventions modified
Mayo ClinicPhase 2 NCT03418038 Registry history of NCT03418038 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 15, 2026 to Apr 15, 2027
Also in this update: Primary completion date changed from estimate of Aug 15, 2026 to Apr 22, 2020
Beth ChristianPhase 1 NCT02992522 Registry history of NCT02992522 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
FamiCordTxPhase 1 NCT06593145 Registry history of NCT06593145 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-15 | NCT07875413 Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory… | AbelZeta Inc. new | Phase 2 |
| 2026-09-30 | NCT07848672 Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP… | The Affiliated People's Hospital of Ningbo University new | Phase 2/3 |
| 2026-09-25 | NCT07842198 Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy | Zealand University Hospital new | Phase 2 |
| 2026-09-16 | NCT07823829 A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma | UCARsgen Biotech Limited new | Phase 1/2 |
| 2026-09-14 | NCT07817641 Proton Therapy for Mediastinal Lymphoma (PROMLY) | Rigshospitalet, Denmark new | |
| 2026-09-10 | NCT07812493 Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS… | Pengpeng Xu new | Phase 2 |
| 2026-09-10 | NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… | University of West Attica new | |
| 2026-09-09 | NCT07808827 A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy… | Shanghai Junshi Bioscience Co., Ltd. new | Phase 3 |
| 2026-08-24 | NCT07782944 CD38 Targeted -PET/ CT for Multiple Myeloma | Guilin Medical University, China new | |
| 2026-08-18 | NCT07771361 BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma… | Luminary Therapeutics new | Phase 2 |
| Early Phase 1 | 10 | |
| Phase 1 | 121 | |
| Phase 1/2 | 84 | |
| Phase 2 | 222 | |
| Phase 2/3 | 10 | |
| Phase 3 | 42 | |
| Phase 4 | 2 |
Ruijin Hospital (34) · National Cancer Institute (NCI) (22) · City of Hope Medical Center (17) · Sun Yat-sen University (12) · The First Affiliated Hospital with Nanjing Medical University (11) · Fondazione Italiana Linfomi - ETS (10) · Genmab (10) · Memorial Sloan Kettering Cancer Center (10) · M.D. Anderson Cancer Center (8) · Institute of Hematology & Blood Diseases Hospital, China (7)